List of Excipients in Branded Drug TOREMIFENE CITRATE

Generic Drugs Containing TOREMIFENE CITRATE

Company	Ingredient	NDC	Excipient
Rising Pharma Holdings Inc	toremifene citrate	64980-404	CELLULOSE, MICROCRYSTALLINE
Rising Pharma Holdings Inc	toremifene citrate	64980-404	COPOVIDONE
Rising Pharma Holdings Inc	toremifene citrate	64980-404	LACTOSE MONOHYDRATE
Rising Pharma Holdings Inc	toremifene citrate	64980-404	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in TOREMIFENE CITRATE?

# Of NDCs	Excipient
3	CELLULOSE, MICROCRYSTALLINE
1	COPOVIDONE
3	LACTOSE MONOHYDRATE
3	MAGNESIUM STEARATE

Last updated: September 3, 2026

Toremifene citrate is a mature, orally administered selective estrogen receptor modulator with limited originator exclusivity and no biosimilar barrier. The commercial opportunity is primarily in low-cost generic tablets, differentiated immediate-release formulations, and specialty products that improve dissolution, dose flexibility, adherence, or tolerability. The main technical constraint is not excipient novelty alone. It is demonstrating bioequivalence while managing toremifene’s limited aqueous solubility, food effects, tablet stability, and clinically relevant QT-prolongation warnings.

Toremifene Citrate Excipient Strategy and Commercial Opportunities

What is the regulatory and commercial status of toremifene citrate?

Toremifene citrate is the citrate salt of toremifene, a nonsteroidal selective estrogen receptor modulator. In the United States, the reference product Fareston is marketed as a 60 mg oral tablet for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor-positive or unknown tumors.[1]

Attribute	Toremifene citrate
Active ingredient	Toremifene citrate
Reference brand	Fareston
Dosage form	Immediate-release tablet
Strength	60 mg
FDA indication	Metastatic breast cancer in postmenopausal women
Original U.S. approval	1997
Product type	Small-molecule drug
FDA pathway for competition	ANDA generic pathway
Biosimilar exposure	None
Key safety issue	QT prolongation and torsades de pointes risk
Main commercial setting	Generic oncology oral solid dose

The reference product’s label identifies a conventional tablet excipient system that includes lactose monohydrate, microcrystalline cellulose, povidone, sodium starch glycolate, magnesium stearate, and colloidal silicon dioxide.[1] This composition indicates a standard direct-compression or wet-granulation platform rather than a proprietary modified-release delivery system.

Toremifene has no biologic manufacturing barrier. Competition is therefore driven by formulation execution, regulatory compliance, manufacturing cost, supply reliability, and commercial access rather than biosimilar interchangeability rules.

What patents protect toremifene citrate and when does it lose exclusivity?

The principal U.S. exclusivity period for toremifene citrate has expired. Fareston was approved in 1997, and any original compound or composition patents associated with the product are no longer expected to block ordinary generic entry in the United States.[1,2]

Exclusivity category	Current assessment
New chemical entity exclusivity	Expired
Original compound patent estate	Expired
U.S. Orange Book blocking position	No material current barrier expected
Method-of-use patents	Historical relevance; limited practical blocking value
Formulation patents	No widely recognized active reference-product barrier
Biosimilar exclusivity	Not applicable
Generic entry pathway	ANDA with comparative bioequivalence

The commercial implication is that a sponsor does not need to license the originator’s formulation technology to market a conventional generic. A new applicant can generally design around historical patents while matching the reference product’s quality and bioequivalence profile.

Patent risk can still arise from later-filed patents covering specific solid dispersions, particle-size distributions, polymorphs, combinations, dosing regimens, or oncology uses. Such patents would need to be evaluated against the actual formulation and proposed labeling. A formulation patent has limited value if it cannot support a commercially differentiated product or withstand an obviousness challenge.

How many patents cover toremifene citrate?

The historical toremifene estate included patents directed to the compound, estrogen-receptor modulation, pharmaceutical compositions, and therapeutic use. The practical U.S. blocking estate is now substantially weaker because the product has been marketed for more than two decades.

A current freedom-to-operate review should distinguish:

1. Expired compound and composition patents.
2. Abandoned or expired method-of-use claims.
3. Live third-party patents on nanoparticles, amorphous dispersions, co-crystals, or alternative salts.
4. Manufacturing patents covering intermediates or impurity-control processes.
5. Foreign patents that remain relevant in markets with different patent terms.

The absence of a meaningful U.S. reference-product patent barrier does not eliminate patent risk for a differentiated reformulation.

What excipients are used in the reference toremifene citrate tablet?

The Fareston tablet uses conventional excipients selected for manufacturability and immediate release.[1]

Excipient	Likely functional role
Lactose monohydrate	Diluent and tablet-mass builder
Microcrystalline cellulose	Diluent, dry binder, compression aid
Povidone	Binder
Sodium starch glycolate	Superdisintegrant
Magnesium stearate	Lubricant
Colloidal silicon dioxide	Glidant and anti-caking agent

This platform is commercially attractive because it uses widely available, low-cost materials with established regulatory histories. It also provides a straightforward generic development target.

The main development risk is excipient-dependent dissolution variability. Magnesium stearate can slow wetting when over-lubrication occurs. Sodium starch glycolate can lose performance when exposed to excessive granulation moisture or compression force. Lactose and povidone can affect granule density, tablet hardness, and disintegration time. These variables matter because a generic applicant must establish comparable dissolution and bioequivalence, not merely reproduce the ingredient list.

Which excipient strategy is most suitable for a generic toremifene tablet?

A conventional immediate-release formulation is the lowest-risk commercial strategy. The target should be a 60 mg tablet with:

• A robust diluent system based on microcrystalline cellulose and lactose or a lactose-free alternative.
• Povidone or another established binder at a level that maintains granule strength without delaying disintegration.
• Sodium starch glycolate or crospovidone for rapid tablet breakup.
• Controlled magnesium stearate addition and lubrication time.
• Colloidal silicon dioxide to improve powder flow.
• Film coating only if needed for appearance, swallowability, moisture protection, or taste masking.

Lactose-containing versus lactose-free formulations

The reference product contains lactose monohydrate.[1] A lactose-free formulation can create a practical differentiation point for patients with lactose intolerance or for markets where lactose labeling is commercially sensitive. Microcrystalline cellulose, mannitol, dibasic calcium phosphate, or partially pregelatinized starch could replace lactose.

A lactose-free formulation must be tested for:

• Tablet tensile strength.
• Friability.
• Disintegration.
• Dissolution across pH conditions.
• Moisture uptake.
• Content uniformity.
• Stability under accelerated conditions.
• Compatibility with the citrate salt.

Lactose removal is unlikely to create strong patent protection by itself. Its value is commercial and operational: broader excipient acceptability, alternative supplier qualification, and potential positioning for hospital or specialty-pharmacy channels.

Direct compression versus wet granulation

Direct compression can reduce equipment requirements, processing time, and manufacturing cost. It is viable if the active pharmaceutical ingredient has acceptable flow, compressibility, and content-uniformity characteristics.

Wet granulation may be preferable when the API has poor flow, segregation risk, low-dose uniformity concerns, or inadequate compactability. For a 60 mg strength, active loading is material but does not automatically require granulation. The selected process should be based on API particle-size distribution, bulk density, electrostatic behavior, and blend uniformity.

What formulation patents could protect a differentiated toremifene product?

Potential formulation claims could target solubility enhancement, controlled release, dosing flexibility, or improved stability. The strongest opportunities are likely to involve a measurable clinical or pharmacokinetic advantage rather than a simple excipient substitution.

Amorphous solid dispersions

Toremifene citrate may be suitable for investigation in amorphous solid dispersions if dissolution or absorption is limited by crystalline lattice energy or poor aqueous solubility. Candidate polymers include:

• Hypromellose acetate succinate.
• Polyvinylpyrrolidone.
• Copovidone.
• Soluplus-type graft copolymers.
• Hydroxypropyl methylcellulose.

Commercial benefits could include faster dissolution, reduced food dependence, or lower dose variability. Risks include recrystallization, moisture sensitivity, residual solvent control, and scale-up complexity.

Lipid-based systems and self-emulsifying formulations

A lipid-based formulation could improve apparent solubilization and reduce dissolution dependence. Useful excipient classes include medium-chain triglycerides, mono- and diglycerides, nonionic surfactants, and cosolvents.

This approach is less attractive for a standard generic because it may require additional comparative clinical or pharmacokinetic work. It could be relevant for a new formulation seeking a 505(b)(2) pathway or a non-U.S. hybrid application.

Nanoparticles and micronized API

Particle-size reduction can increase surface area and dissolution rate. The principal challenge is proving that the smaller particle distribution remains stable during blending, compression, and storage. Nanoparticle claims may support stronger IP than a conventional tablet, but regulatory complexity and manufacturing cost increase.

Orally disintegrating tablets

An orally disintegrating toremifene product could target patients with dysphagia, advanced disease, or difficulty swallowing conventional tablets. Mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and flavor systems are common platform excipients.

The main limitation is taste. Toremifene’s bitterness would require taste masking through coating, complexation, ion exchange, or polymeric barriers. Because the dose is 60 mg, tablet size and mouthfeel also require attention.

Modified-release formulations

A once-daily immediate-release tablet already provides the labeled regimen. Modified release would therefore need to offer a defined advantage, such as reduced peak exposure, lower adverse-event risk, or improved pharmacokinetic consistency. Without a clinically relevant benefit, modified release would add development cost without a clear reimbursement premium.

How does toremifene’s safety profile affect excipient selection?

The FDA label carries a boxed warning for QT prolongation and the risk of torsades de pointes.[1] Toremifene is contraindicated in patients with known or suspected QT prolongation, hypokalemia, or hypomagnesemia, and it should not be used with certain QT-prolonging drugs.

Excipient selection must therefore avoid indirect pharmacokinetic effects that could increase exposure or alter absorption unpredictably. Development should focus on:

• Comparable systemic exposure to the reference product.
• Absence of excessive food-effect amplification.
• Consistent dissolution across pH conditions.
• Tight control of assay and content uniformity.
• Avoidance of excipients with meaningful CYP3A4 inhibition or induction.
• Evaluation of gastric-retention or highly viscous systems that could alter absorption.

Toremifene is metabolized principally through CYP3A4 pathways, and strong CYP3A4 inhibitors can increase exposure.[1] An excipient does not normally create the same interaction magnitude as a potent drug inhibitor, but high levels of surfactants, absorption enhancers, or novel lipid systems require pharmacokinetic scrutiny.

What commercial opportunities exist for toremifene citrate?

Low-cost U.S. generic tablets

The primary opportunity is a conventional ANDA product. A generic sponsor can compete on:

• API sourcing.
• Tablet manufacturing cost.
• Reliable availability.
• Wholesaler and specialty-pharmacy contracting.
• Packaging efficiency.
• Low minimum order quantities.
• Hospital and government supply contracts.

Because the market is mature and the indication is oncology-related, supply continuity can be more valuable than aggressive price reduction. A sponsor with dual API sources and validated alternate excipient suppliers can reduce shortage risk.

Private-label and regional products

Toremifene can support private-label distribution in markets where Fareston or a local generic is available. Regional opportunities depend on national registrations, patent status, local oncology guidelines, and reimbursement.

The active ingredient is especially suited to markets where:

• Tamoxifen resistance is clinically relevant.
• Aromatase inhibitors are poorly tolerated or contraindicated.
• Physicians continue to use selective estrogen receptor modulators.
• Oral oncology medicines are distributed through specialty pharmacies.

Differentiated 505(b)(2) products

A 505(b)(2) strategy could support a new dosage form, improved solubility, altered dosing, or a patient-focused formulation. The commercial case requires a demonstrable advantage over the established 60 mg tablet.

Potential claims could include:

• Improved bioavailability at a lower dose.
• Lower interpatient variability.
• Reduced food effect.
• Easier administration for dysphagic patients.
• Improved stability in hot and humid climates.
• Reduced tablet size.
• A pediatric or specialty formulation, subject to an appropriate clinical rationale.

Combination products

Toremifene could theoretically be paired with endocrine therapies or supportive-care agents, but combination development would face clinical, regulatory, and patent hurdles. A fixed-dose combination is unlikely to be commercially attractive without evidence that it improves adherence or outcomes.

What generic entry risks exist for toremifene citrate?

Risk	Commercial impact	Mitigation
Small market size	Limits return on formulation investment	Use low-cost platform and contract manufacturing
Oncology supply expectations	Shortages can trigger customer loss	Qualify dual API and excipient suppliers
Dissolution variability	Can delay ANDA approval	Optimize particle size, granulation, and lubrication
QT-related labeling	Limits broad use	Maintain exact safety labeling and pharmacokinetic comparability
Limited clinical differentiation	Restricts premium pricing	Focus on adherence, swallowing, stability, or access
Historical patent uncertainty	Can create litigation costs	Conduct current U.S. and foreign FTO review
API impurity control	May affect stability and compliance	Establish impurity profile and validated methods
Generic price erosion	Reduces margin	Target underserved or supply-constrained channels

A Paragraph IV challenge is possible when a listed patent remains in the Orange Book. For toremifene, the age of the reference product makes a patent-driven launch strategy less central than formulation economics and market access. Any ANDA sponsor should still review the current Orange Book listing for NDA 020497 before filing.[2]

Which companies are challenging or competing with Fareston?

The competitive set includes generic manufacturers of toremifene citrate and alternative endocrine therapies. The most important substitutes are tamoxifen, anastrozole, letrozole, exemestane, and fulvestrant, although these products differ in mechanism, administration, patient population, and guideline placement.

Product class	Representative products	Competitive relevance
Toremifene	Fareston and generics	Direct substitute
Tamoxifen	Generic tamoxifen	Closest oral SERM comparator
Aromatase inhibitors	Anastrozole, letrozole, exemestane	Common endocrine alternatives
SERD therapy	Fulvestrant and newer oral agents	Different mechanism and treatment setting
Combination endocrine therapy	Various branded and generic combinations	May compete in advanced disease

Competition is therefore therapeutic, not only product-level. A toremifene sponsor should position around tolerability, physician familiarity, availability, and cost rather than assume that generic substitution automatically creates demand.

What is the geographic coverage and manufacturing opportunity?

The United States is the clearest mature generic market because of the established NDA and ANDA pathway. Europe and other jurisdictions require separate assessment of national marketing authorizations, local reference products, data exclusivity, and patent status.

Manufacturing opportunity is strongest for companies that already produce oral oncology tablets. Existing capabilities can reduce incremental investment in:

• High-containment handling.
• Potent-compound cleaning validation.
• Low-dose blend uniformity.
• Film coating.
• Stability testing.
• Specialty packaging.

The API supply chain may be more important than the excipient system. A formulation using standard compendial excipients can be replicated by many manufacturers. Reliable, compliant toremifene citrate API supply is more likely to differentiate a vendor.

How strong is the patent estate for a new toremifene excipient formulation?

A new formulation can have moderate patent strength if it demonstrates a defined technical effect and uses a non-obvious combination of composition and process claims. The strongest claim packages would combine:

1. Composition claims covering the API, polymer, surfactant, or particle-size range.
2. Process claims covering preparation and stabilization.
3. Dissolution or pharmacokinetic performance limits.
4. Use claims tied to a clinically relevant patient population.
5. Device or packaging claims where moisture or light sensitivity is material.

A claim based only on replacing lactose with mannitol or changing the lubricant is likely to face obviousness challenges. A formulation that materially reduces food effect or improves bioavailability has stronger commercial and patent value.

What is the outlook for toremifene citrate revenue exposure?

Public revenue exposure is difficult to quantify because Fareston has a mature, limited market and generic sales are often distributed across private-label channels. The commercial case should be modeled using scenario assumptions rather than historical brand sales alone.

Scenario	Product strategy	Expected economics
Base case	Conventional 60 mg generic tablet	Low development cost, price competition
Upside case	Reliable supply plus lactose-free or smaller tablet	Moderate differentiation, limited premium
Specialty case	ODT or dysphagia-focused product	Higher development cost, narrower market
Reformulation case	Solubility-enhanced or food-effect-reduced product	Potential premium, higher regulatory burden
Regional case	Localized supply in underserved markets	Margin depends on registration and reimbursement

The highest-probability return comes from a conventional tablet with disciplined manufacturing costs. A novel excipient platform requires a larger addressable market or a clear clinical advantage to justify development.

Key Takeaways

• Toremifene citrate is a mature small-molecule oncology product with expired primary U.S. exclusivity.
• Fareston is a 60 mg immediate-release tablet containing conventional excipients.
• The lowest-risk strategy is an ANDA generic using a lactose-based or lactose-free immediate-release formulation.
• The main formulation variables are dissolution, lubrication, disintegration, particle size, content uniformity, and stability.
• Amorphous dispersions, lipid systems, micronized API, and orally disintegrating tablets offer lifecycle opportunities but increase regulatory and manufacturing complexity.
• QT prolongation and CYP3A4-related exposure concerns make pharmacokinetic comparability and excipient conservatism important.
• Patent value is more likely to arise from demonstrated solubility, food-effect, or adherence improvements than from routine excipient substitution.
• Commercial success depends more on API supply, manufacturing reliability, and access channels than on originator patent barriers.
• Biosimilar competition is irrelevant because toremifene is a small molecule.
• A conventional generic has the clearest risk-adjusted opportunity; differentiated formulations require a specific patient or pharmacokinetic advantage.

FAQs

Is toremifene citrate a good candidate for an orally disintegrating tablet?

Yes, but the 60 mg dose and bitter taste create formulation challenges. Taste masking, tablet size, mechanical strength, and rapid disintegration would need to be demonstrated.

Can lactose be removed from a generic toremifene formulation?

Yes. Microcrystalline cellulose, mannitol, dibasic calcium phosphate, or starch-based excipients could replace lactose, subject to bioequivalence, stability, and performance testing.

Does toremifene citrate require a biosimilar application?

No. Toremifene citrate is a chemically synthesized small molecule. A conventional generic would generally use the ANDA pathway rather than the biosimilar pathway.

Could a solubility-enhanced toremifene product receive new patent protection?

Potentially. Patentability would depend on novelty, non-obviousness, enablement, and proof of a measurable technical benefit such as improved dissolution, reduced food effect, or improved exposure consistency.

Is the reference Fareston excipient composition mandatory for generic approval?

No. A generic applicant does not generally need to duplicate every inactive ingredient. The proposed formulation must meet applicable safety, quality, bioequivalence, labeling, and regulatory requirements.

References

1. U.S. Food and Drug Administration. (2024). Fareston (toremifene citrate) tablets prescribing information. FDA-approved labeling.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2015). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. FDA Guidance for Industry.

4. U.S. Food and Drug Administration. (2022). ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant or natural origin: Guidance for industry. FDA.

5. National Library of Medicine. (2024). DailyMed: Fareston-toremifene citrate tablet. U.S. National Library of Medicine.